Arteris, Inc.
13.61-0.04 (-0.29%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · AIP · USD
Key Stats
Market Cap
580.47MP/E (TTM)
-Basic EPS (TTM)
-0.81Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Arteris posted solid Q2 FY2025 revenue of $16.5M, up 13% y/y from $14.6M and 11% q/q from Q1's $16.5M (derived), fueled by new licenses and stronger royalties from existing customers ramping production. Gross profit hit $14.8M for an 89% margin, edging up from 90% last year, while operating loss narrowed to $8.2M from $7.4M y/y amid R&D investments in AI-driven SoC tech. Diluted EPS of -$0.22 matched last year's figure on 41.8M shares, with no anti-dilution effects. Cash climbed to $16.1M plus $21.9M short-term investments, generating $0.4M operating cash flow for H1; vendor debt sits at $2.5M with no revolver. Equity investment in Transchip dragged $0.8M, but no impairment flagged. Non-GAAP metrics not disclosed in the 10-Q. China exposure, now 25% of revenue, risks U.S. export curbs.
8-K
Arteris Q2 revenue up 13%
Arteris reported Q2 2025 revenue of $16.5 million, up 13% year-over-year, with record ACV plus royalties hitting $69.1 million—a 15% jump—and RPO surging 28% to $99.3 million. Key wins included AMD licensing FlexGen for AI chiplets and Whalechip adopting FlexNoC for data center AI, while new Magillem Packaging software targets faster chiplet assembly. Yet operating losses held steady at $8.2 million. Updated full-year guidance projects ACV plus royalties of $72.0-$78.0 million, but competition looms large.
8-K
Arteris annual meeting results
Arteris, Inc. held its annual stockholder meeting on June 3, 2025, where shareholders elected K. Charles Janac and S. Atiq Raza as Class I directors for terms until 2028, with Janac receiving strong support of 27.3 million votes for and Raza facing more withheld votes at 3.3 million. Stockholders also ratified Deloitte & Touche LLP as the independent auditor for fiscal 2025, passing with 31.5 million votes in favor. Both outcomes affirm governance continuity. No major disruptions emerged.
10-Q
Q1 FY2025 results
Arteris posted solid Q1 FY2025 results, with revenue climbing 28% year-over-year to $16.5 million, fueled by stronger licensing deals and a 43% jump in variable royalties to $1.2 million, while gross profit margins held steady around 91%. Operating losses narrowed to $7.7 million from $9.1 million last year, thanks to tighter expense controls amid rising R&D and sales investments, and diluted EPS improved to $(0.20) from $(0.25) on 40.9 million weighted shares—anti-dilution kept it aligned with basic. Cash from operations hit $2.9 million, up sharply from $0.5 million, lifting cash and equivalents to $16.4 million with $38.7 million in total liquidity; vendor debt sits low at $1.8 million. No major M&A or regulatory hits this quarter. Yet competition from in-house IP teams at big chipmakers remains a persistent drag.
8-K
Arteris Q1 revenue surges 28%
Arteris reported Q1 2025 revenue of $16.5 million, up 28% year-over-year, with record ACV plus royalties hitting $66.8 million—a 15% jump—fueled by demand in enterprise computing, communications, and automotive sectors. The company swung to positive non-GAAP free cash flow of $2.7 million while narrowing its non-GAAP operating loss to $3.2 million. Record highs. Updated full-year guidance projects ACV plus royalties of $71.0–$79.0 million and revenue of $65.0–$71.0 million, though macroeconomic uncertainty lingers.
ACLS
Axcelis Technologies, Inc.
83.14+0.85
ADI
Analog Devices, Inc.
235.04-4.31
AMBA
Ambarella, Inc.
86.00-0.30
AMD
Advanced Micro Devices, Inc.
264.33+6.32
ARM
Arm Holdings plc
170.39-2.70
AVGO
Broadcom Inc.
385.98+13.01
CEVA
CEVA, Inc.
27.87-0.44
MCHP
Microchip Technology Incorporat
62.54-1.10
MXL
MaxLinear, Inc
15.21-0.56
SNPS
Synopsys, Inc.
455.34-1.49